Sony Pixel Power calrec Sony

December 08, 2021

09/12/2021

Calibr announces preliminary clinical data from first-in-human clinical trial of switchable CAR-T Cells (CLBR001 SWI019) in lymphoma patients at 63rd Annual ASH Meeting

Two of the first three patients in the lowest dose cohort experienced a complete response to therapy with the longest response being 11 months (ongoing) at the time of data cut-off

The novel switchable CAR-T therapy showed a favorable profile with no toxicities associated with the cell product (CLBR001) alone, validating the universal platform approach to cell therapy

December 08, 2021

LA JOLLA, CA Calibr, a division of Scripps Research focused on the bench to bedside development of transformative medicines, will present preliminary data on the development of a novel switchable CAR-T cell platform for patients with relapsed/refractory lymphoma and leukemia. Preclinical IND-enabling studies supporting the first-in-human clinical study will be presented on December 11 at 5:30 p.m. and the clinical data will be presented on December 12 at 6:00 p.m. at the 63rd Annual ASH meeting.

CLBR001 SWI019 is the first clinical demonstration of Calibr's novel switchable CAR-T cell platform technology, in which the activity of a universal CAR-T cell product (CLBR001) is controlled through dosage of an antibody-based molecule targeting CD19 referred to as a switch (SWI019). The approach represents a paradigm shift from conventional CAR-T cell therapy in that the activity of the CAR-T cells can be switched on or off through dosing of the switch to the patient. This type of switchable control over the cells is expected to improve safety T cell durability of the therapy. Importantly, the CLBR001 switchable CAR-T is universal; by changing the switch, the CAR-T cells can be programmed to attack different antigen targets and thereby treat multiple cancers.

As of the data cutoff, 5 patients (2 with mantle cell lymphoma (MCL), 2 with follicular lymphoma (FL), and 1 with marginal zone lymphoma (MZL)) had been treated across two cohorts. Two of the first three patients who received the lowest doses of CLBR001 and SWI019 in cohort 1 of the dose escalation trial experienced a complete response to treatment as assessed by Lugano criteria. Durability of the response appears promising, with the longest response ongoing at 11 months. Treatment in cohort 2 is ongoing.

In the preliminary safety and tolerability data for CLBR001 SWI019, no adverse events related to the cell product CLBR001 alone were reported, validating the design of the universal cell product to be functionally off in the absence of SWI019. Following administration of the switch molecule SWI019, two subjects experienced transient cytokine release syndrome (CRS) of severity grades 1 and 3. The subject who experienced Grade 1 CRS also experienced Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS). These cases of CRS/ICANS resolved quickly with typical CRS treatment followed by holding or reducing SWI019 dose, supporting the ability to adjust the CAR-T response in real time.

We are very excited by initial signs of activity even at the lowest doses of CLBR001 and SWI019, says Travis Young, PhD, Calibr's vice president of biologics and lead on the CAR-T development at Calibr. We believe this underscores the potential of this therapy to not only benefit patients with blood cancers, but patients with solid tumors as well.

Liana Nikolaenko, MD, from City of Hope is the lead author on the poster presentation. Switchable CAR-T cell platform, as designed by Calibr, is a remarkable technology enabling a delivery of the targeted therapy for patients with relapsed or refractory B-cell malignancies with a unique approach to mitigate potential toxicities that could be associated with CAR-T cell treatment, which can be severe and life-threatening, says Nikolaenko. The preliminary results of this novel approach are encouraging.

Calibr has partnered the switchable CAR-T cell platform with AbbVie and together they are collaborating on developing the switchable CAR-T cell platform for solid tumor indications. AbbVie holds certain rights to commercialization.

Presentation times

Poster: 2822 First in Human Study of an On/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 SWI019)

Session Date/Time: Sunday, December 12, 2021, 6:00 p.m.--8:00 p.m.

Presenter: Liana Nikolaenko, MD, City of Hope

Poster: 1695 IND-Enabling Studies of a Switchable Chimeric Antigen Receptor-T Cell (CLBR001 SWI019) to Support First in Human Clinical Study

Session Date/Time: Saturday, December 11, 2021, 5:30 p.m.--7:30 p.m.

Presenter: Eduardo Laborda, PhD, Calibr at Scripps Research

About CLBR001 SWI019:

Calibr at Scripps Research is currently enrolling patients with B cell malignancies including lymphomas and chronic lymphocytic leukemia to an open label Phase I clinical study to test the safety and tolerability of CLBR001 SWI019 (NCT04450069). Up to 30 patients may be enrolled in the multi-center dose escalation trial to determine the optimal dose of CLBR001 and SWI019. Additional information on the study can be found at https://clinicaltrials.gov/ct2/show/NCT04450069.

About Calibr at Scripps Research:

Calibr was founded on the principle that the creation of new medicines can be accelerated by pairing world-class biomedical research with state-of-the-art drug discovery and development capabilities. Leveraging the unique scientific framework of Scripps Research, Calibr has created a portfolio of drug candidates based on Scripps technologies, and is shaping a new paradigm for advancing nonprofit biomedical research to impact patients while re-investing in further innovative research.

Cancer Calibr Calibr
LINK: https://www.scripps.edu/news-and-events/press-room/2021/20211208-calib...
See more stories from scripps

More from Scripps

13/03/2024

March 13, 2024

New computational strategy boosts the ability of drug designers to target proteins inside the membrane Customized-design approach could streamline the design of...

29/02/2024

February 29, 2024

Scripps Research scientists reveal how first cells could have formed on Earth New phospholipid discovery brings researchers closer to understanding how primordi...

29/02/2024

February 28, 2024

How molecular handedness emerged in early biology Scripps Research chemists fill a major gap in origin-of-life theories. February 28, 2024 LA JOLLA, CA Mole...

22/02/2024

February 21, 2024

Snaking toward a universal antivenom Scripps Research scientists discovered antibodies that protect against a host of lethal snake venoms. February 21, 2024 ...

06/02/2024

February 06, 2024

Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases AbbVie...

26/01/2024

January 25, 2024

Re-energizing mitochondria to treat Alzheimer's disease Scripps Research team restored neuron-to-neuron connections in human cells. January 25, 2024 LA JO...

24/01/2024

January 04, 2024

100 years of Science Changing Life: Scripps Research celebrates a century of transforming human health For the last century, institute leaders and renowned scie...

23/01/2024

January 23, 2024

New technology lets researchers track brain cells' off switches The method could shed light on what goes awry in numerous brain conditions when neurons ar...

09/01/2024

January 08, 2024

Three decades of giving: Announcing the Calibr-Skaggs Institute for Innovative Medicines The ALSAM Foundation, founded by the Skaggs family, provides lasting g...

04/01/2024

January 03, 2024

Life science entrepreneur Gene Lay joins Scripps Research Board of Directors Lay, founder of the global biotech company BioLegend, brings invaluable experience ...

21/12/2023

December 20, 2023

Taming a plant-derived toxin Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments. ...

19/12/2023

December 18, 2023

Scripps Research Executive Vice President Eric Topol gives TED talk on transformative power of AI in medicine Topol provides an overview of how AI models can i...

13/12/2023

December 12, 2023

New AI-powered algorithm could better assess people's risk of common heart condition Early detection of atrial fibrillation can reduce the risk of stroke an...

07/12/2023

December 06, 2023

Nanoparticle flu vaccine design shows promise in early tests Scripps Research-designed vaccine could provide broad, enduring protection against influenza A str...

16/11/2023

November 15, 2023

Numerous Scripps Research scientists named Highly Cited Researchers Clarivate's annual, global list represents researchers who have demonstrated significant...

07/11/2023

November 06, 2023

Multiple sclerosis drug invented at Scripps Research slows long-term devastating disease progression Late-breaking data reinforces the effectiveness and safety ...

05/10/2023

October 04, 2023

Keren Lasker named a 2023 Moore Inventor Fellow The prestigious award will support Lasker's inventive research in membraneless organelles and their applica...

22/09/2023

September 21, 2023

Michael Bollong named a 2023 Amgen Young Investigator The prestigious award will support Bollong's research identifying new molecular targets and therapeuti...

09/09/2023

September 08, 2023

Philip Dawson receives 2024 American Chemical Society National Award Dawson is honored with the Arthur C. Cope Late Careers Scholar Award for his foundational c...

07/09/2023

September 06, 2023

Scripps Research chemists devise a method for C-H activation of alcohols The method represents a new toolkit for making drugs and other compounds. September 06...

31/08/2023

August 30, 2023

Scripps Research receives $1.5M to surveil infectious disease threats in wastewater Bill & Melinda Gates Foundation award to support the development of multi-pa...

16/08/2023

August 16, 2023

How cold temperatures trigger the brain to boost appetite Scripps Research scientists' discovery could lead to new weight loss and metabolic health treatmen...

08/08/2023

August 07, 2023

Human antibody that targets carfentanil, fentanyl and related opioids reverses overdose effects in preclinical study Scripps Research-developed antibody therapy...

04/08/2023

August 03, 2023

How sensory neurons impact the gut Scripps Research scientists show that the receptor PIEZO2 in sensory neurons controls gut motility and transit time, which a...

26/07/2023

July 26, 2023

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets The expanded strategic collaboration will advan...

23/07/2023

July 21, 2023

Scripps Research scientists develop AI-based tracking and early-warning system for viral pandemics Machine-learning system effectively predicts emergence of pro...

19/07/2023

July 19, 2023

Monitoring T cells may allow prevention of type 1 diabetes Scripps Research study shows that analyzing T cells in blood samples could be used to select at-risk ...

19/07/2023

July 18, 2023

Scripps Research mourns passing of leading organic chemist Albert Eschenmoser Eschenmoser pioneered key reactions in synthetic chemistry and shaped the understa...

15/06/2023

June 14, 2023

Scripps Research awarded $46.8 million by NIH to promote human health through innovative translational science and training The Translational Institute is harne...

13/06/2023

June 13, 2023

Scripps Research's Danielle Grotjahn named 2023 Pew Scholar in the Biomedical Sciences The award will support Grotjahn's study of how cells assemble the...

31/05/2023

May 31, 2023

Crossing the ring: new method enables C-H activation across saturated carbocycles Scripps Research chemists add another powerful tool to their molecular editin...

24/05/2023

May 23, 2023

Scripps Research develops behind-the-scenes tool for better biomedical data discovery The new resource makes datasets more discoverable for life science communi...

19/05/2023

May 15, 2023

Scripps Research neuroscientist Hollis Cline elected to American Academy of Arts and Sciences Cline is recognized for her discoveries about the role of sensory ...

19/05/2023

May 18, 2023

Scripps Research's Skaggs Graduate School awards doctoral degrees to 31st graduating class Commencement ceremony will be livestreamed via Zoom and on instit...

13/05/2023

May 12, 2023

A better route to benzocyclobutenes, sought-after building blocks for drugs Scripps Research chemists devise a new, C-H activation-based method for the synthesi...

09/05/2023

May 08, 2023

Renowned Scripps Research professor Jeffery Kelly elected to National Academy of Sciences Kelly's groundbreaking work on protein misfolding has led to thera...

28/04/2023

April 27, 2023

Mirror-image molecules pave new path for cancer drug discovery By comparing how mirror image versions of small molecules impact clusters of proteins, Scripps R...

22/04/2023

April 21, 2023

How alcohol consumption contributes to chronic pain A Scripps Research team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and...

21/04/2023

April 20, 2023

Xin Jin receives dual awards to study autism risk genes in neurodevelopment Major grants from the National Institutes of Health and California Institute for Reg...

20/04/2023

April 19, 2023

Trim the sugar: New HIV vaccine design improves immune response Scripps Research vaccine candidate headed for clinical trials. April 19, 2023 LA JOLLA, CA A...

18/04/2023

April 17, 2023

Therapeutic can seek and destroy potent opioid to treat overdoses Scripps Research chemists developed a new biologic to work against the synthetic opioid carfen...

07/03/2023

March 06, 2023

How heavy alcohol consumption increases brain inflammation The findings by a Scripps Research team point toward a potential new drug target for treating alcohol...

02/03/2023

March 01, 2023

Scientists find human antibodies that can block multiple coronaviruses including SARS-CoV-2 Results from a Scripps Research and UNC team pave the way for a vacc...

28/02/2023

February 28, 2023

$10 million grant funds Scripps Research Alcohol Research Center through its 50th year The five-year grant supports research into the neurobiology of alcohol us...

28/02/2023

February 27, 2023

Immune system drug shows promise in treating alcohol use disorder, a Scripps Research clinical trial reports Scientists at Scripps Research found that apremilas...

23/02/2023

February 16, 2023

Chemically poisoned protein acts as a molecular switch to spur cancer formation The discovery triggered development of a new potential drug to eliminate tumor...

23/02/2023

February 23, 2023

Two new papers demonstrate use of Outbreak.info as one-stop online source for COVID data Scripps Research scientists highlight the need for continued monitorin...

15/02/2023

February 15, 2023

Calibr and Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel candidate tuberculosis treatment compound Calibr transitions i...

08/02/2023

February 07, 2023

Scripps Research Professor Jeffery Kelly awarded 2023 Wolf Prize in Chemistry Kelly receives the prestigious award for his seminal discoveries in protein-foldin...

31/01/2023

January 30, 2023

Experimental anti-depression drug may also be useful in treating alcohol use disorder Investigational, clinical-stage antidepressant MAP4343 shown to reduce alc...